glp-1 oral drugs US FDA accepts Novo Nordisk's application for Wegovy for weight loss Oral GLP-1 Weight Loss: Pills

114 Gmez-AceboEAlcam PertejoJAun-CallesD

Costa G, Caputi FF, Serra M, Simola N, Rullo L, Stamatakos S, Sanna F, Germain M, Martinoli MG, Candeletti S, Morelli M, Romualdi P (2021) Activation of antioxidant and proteolytic pathways in the nigrostriatal dopaminergic system after 3,4-methylenedioxymethamphetamine administration: sex-related differences

Preclinical studies have shown that large doses of GLP-1RAs can reduce lipid deposition and plaque volume on the aortic surface of hyperglycemic mice via an AMPK-independent action in streptozotocin (STZ)-induced hyperglycemic and hyperlipidemic mice or type 1 diabetic rats [55]

In late 2023, the FDA added more than a dozen peptides including both BPC-157 and thymosin alpha 1 to its list of substances that should not be compounded because the agency has identified potential significant safety risks. For BPC-157, the agency warned that the peptide could trigger an immune response

But effectiveness is not the only factor that matters